About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $535.48 | Open | |
Volume | 172 | Market Cap | 56.861B |
Yield | Last Dividend |
Forty of the Nation's Most Talented Youn... | 01/21/21 |
TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2021 /PRNewswire/ -- Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. STEM... |
STAT+: Pharmalittle: U.S. health officia... | 01/19/21 |
U.S. officials are pleading for more use of Covid-19 antibody therapies from Eli Lilly and Regeneron Pharmaceuticals that have been plagued by logisti... |
This common drug might save people with ... | 01/15/21 |
A new study suggests that the anti-cholesterol drug Fenofibrate, also known as Ticor, can help treat coronavirus patients. In lab testing with the dru... |
Why Regeneron, Jaguar Health And Seneca ... | 01/13/21 |
Regeneron Pharmaceuticals (NASDAQ: REGN ) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million dose... |
Regeneron To Supply US With Another 1.25... | 01/12/21 |
Biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the signing of a $2.625 billion supply agreement with the U.S. government for i... |
Regeneron says U.S. government to buy 1.... | 01/12/21 |
Regeneron Pharmaceuticals Inc. undefined said late Tuesday that the U.S. government has agreed to buy an additional 1.25 million doses of the company'... |
Global Retinal Biologics Market To Witne... | 01/11/21 |
Global retinal biologics market is expected to gain market growth at a CAGR of 7.60% in the forecast period of 2020 to 2027. Data Bridge Market Resear... |
A Look Into Regeneron Pharmaceuticals Pr... | 12/30/20 |
Right now, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) share price is at $484.95, after a 0.15% gain. Moreover, over the past ??? |
Positive Vaccine News, Brexit, Weak US D... | 12/30/20 |
Major indices worldwide continue the year-end rally on Wednesday as the world progresses on the COVID-19 vaccine front. Moderna Inc (NASDAQ: MRNA ) an... |
Regeneron COVID-19 Antibody Cocktail Sho... | 12/30/20 |
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) disclosed Tuesday that its antibody cocktail showed positive results in early-stage trials for hospital... |
Regeneron Pharmaceuticals : Calls Initia... | 12/29/20 |
By Stephen Nakrosis Regeneron Pharmaceuticals Inc. on Tuesday said initial data from an ongoing Phase 1/2/3 clinical trial of its antibody cocktail in... |
Global Biologics Market 2020-2027:Compet... | 12/17/20 |
???Global Biologics Market???Industry Trends and Forecast to 2027??? focuses on the major drivers and limitations for the key players. These research ... |
U.S. hospitals try 'MAb squads,' infusio... | 12/16/20 |
U.S. hospitals have been slow to embrace COVID-19 antibody drugs from Eli Lilly and Co and Regeneron Pharmaceuticals Inc that have been authorized to ... |
Regeneron pauses patient enrollment in l... | 12/14/20 |
Regeneron Pharmaceuticals Inc said on Monday it was pausing patient enrollment in two trials testing its experimental lymphoma drug, after the U.S. he... |
Regeneron sues Trump administration over... | 12/11/20 |
Regeneron Pharmaceuticals Inc filed a lawsuit on Friday challenging a new rule issued by the Trump administration that aims to lower drug prices by ty... |
Should You Buy Regeneron Stock on the Di... | 12/07/20 |
Shares of health-care company Regeneron Pharmaceuticals (NASDAQ:REGN) are right around oversold territory with the stock trading at a relative strengt... |
CVS is now providing an experimental cor... | 12/07/20 |
CVS Health has started providing coronavirus patients with an antibody drug treatment from Eli Lily. The drug is delivered via an IV and will be admin... |
Scott+Scott Attorneys at Law LLP Continu... | 12/02/20 |
NEW YORK--(BUSINESS WIRE)-- #REGN--Scott+Scott Continues Investigation of Regeneron Pharmaceuticals, Inc.???s Directors and Officers for Breach of Fid... |
Regeneron Pharmaceuticals : U.S. to begi... | 11/23/20 |
The U.S. government will start distributing Regeneron Pharmaceuticals Inc's newly authorized COVID-19 antibody combination on Tuesday, beginning with ... |
A Peek Into The Markets: US Stock Future... | 11/23/20 |
Pre-open movers U.S. stock futures traded higher in early pre-market trade on positive vaccine news. Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) dis... |
Positive Vaccine News, Economic Recovery... | 11/23/20 |
Major indices across Asia, Europe, and the U.S. are trading higher on Monday on positive vaccine news and economic recovery hopes. Regeneron Pharmaceu... |
Regeneron's COVID Treatment Gets Emergen... | 11/22/20 |
The U.S. Food and Drug Administration has issued emergency use authorization for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody ??? |
FDA authorises emergency use of experime... | 11/21/20 |
Regeneron Pharmaceuticals says it expects to have does of 'antibody cocktail' ready for about 80,000 patients by the end of this month |
FDA grants emergency clearance for Regen... | 11/21/20 |
Regeneron Pharmaceuticals (NASDAQ:REGN) says its COVID-19 antibody cocktail casirivimab and imdevimab administered together has received Emergency Use... |
US grants emergency use authorisation to... | 11/21/20 |
The US Food and Drug Administration on Saturday issued an emergency use authorisation for Regeneron Pharmaceuticals Inc's COVID-19 antibody ??? |
Global Bi Syndrome Treatment Market 2020... | 11/20/20 |
This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the mark... |
Present Scenario and Growth Prospects of... | 11/19/20 |
Global Retinal Biosimilars Market Overview: This report provides in-depth study of ???Global Retinal Biosimilars Market??? using SWOT analysis i.e. St... |
Regeneron Included on Dow Jones Sustaina... | 11/16/20 |
(Regeneron Pharmaceuticals) TARRYTOWN, N.Y., Nov. 16, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has ... |
Hold rating | 01/19/21 |
Morgan Stanley maintains Equal-Weight rating and raises Price Target from $527.00 to $553.00 |
Buy rating | 01/14/21 |
Citigroup maintains Buy rating and raises Price Target from $575.00 to $584.00 |
Buy rating | 01/13/21 |
Benchmark upgrades from Hold to Buy rating and announces Price Target of $590.00 |
Strong Buy rating | 12/16/20 |
Credit Suisse maintains Outperform rating and lowers Price Target from $737.00 to $736.00 |
Hold rating | 12/16/20 |
Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $602.00 to $527.00 |
Hold rating | 11/09/20 |
Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $609.00 to $602.00 |
Buy rating | 11/06/20 |
BMO Capital maintains Market Perform rating and raises Price Target from $626.00 to $630.00 |
Strong Buy rating | 11/06/20 |
SVB Leerink maintains Outperform rating and raises Price Target from $650.00 to $653.00 |
Strong Buy rating | 11/06/20 |
Credit Suisse maintains Outperform rating and lowers Price Target from $745.00 to $737.00 |
Date | 2020-11-05 (BMO) | Est. (EPS/Rev.) | $7.09/ 2.09B |
Actual (EPS/Rev.) | $8.36/ $2.29 B | EPS (TTM) | 0 |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
Stock_Options | alps | 92.00 % | Follow |
Spread and Condor Play | Sankar | 65.00 % | Subscribe |
Potential Trading Ideas | Potential Trading | 59.00 % | Follow |
Best Trading Ideas | Best Trading Ideas | 54.00 % | Follow |
A Dozen Plans | Hao | 53.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.